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Abstract
Background: Neoadjuvant chemoradiation therapy for locally unresectable and borderline resectable
pancreatic cancer may allow some patients to a undergo a resection, but whether or not this increases
post-operative morbidity remains unclear.
Methods: The post-operative morbidity of 29 patients with initially locally unresectable/borderline pan-
creatic cancer who underwent a resection were compared with 29 patients with initially resectable
tumours matched for age, gender, the presence of comorbidities (yes/no), American Society of Anesthe-
siology (ASA) score, tumour location (head/body-tail), procedure (pancreaticoduodenectomy/distal pan-
createctomy) and vascular resection (yes /no). Wilcoxon's signed ranks test was used for continuous
variables and McNemar's chi-square test for categorical variables.
Results: Compared with patients with initially resectable tumours, patients who underwent a resection
after pre-operative chemoradiation therapy had similar rates of overall post-operative complications (55%
versus 41%, P = 0.42), major complications (21% versus 21%, P = 1), pancreatic leaks and fistulae (7%
versus 10%, P = 1) and mortality (0% versus 1.7%, P = 1).
Conclusion: Although some previous studies have suggested differences in post-operative morbidity
after chemoradiation, our case-matched analysis did not find statistical differences in surgical morbidity
and mortality associated with pre-operative chemoradiation therapy.
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Introduction
Pancreatic adenocarcinoma is the fourth leading cause of cancer
death in North America and accounts for over 30 000 deaths
annually.1 The incidence and mortality rates are similar and a
major reason for the high fatality rate is that pancreatic carcinoma
often presents at a late stage.2 The greatest chance for long-term
survival is when a complete resection can be performed; however,
this is only possible in about 20% of patients at presentation.3
Neoadjuvant treatment has been investigated both in the setting
of resectable disease at diagnosis and in an attempt to downstage
locally unresectable (stage III) disease for resection.4–8
For locally unresectable or borderline resectable tumours,
partial or complete responses after radiochemotherapy have been
observed with up to 32% of patients coming to resection.4,9,10 As
previously described by this group, the median overall survival
(OS) of patients who initially presented with locally unresectable
pancreatic cancer and experienced enough of a response to
undergo a resection was 25 months from resection and 30 months
since treatment initiation. There was no difference in OS from the
time of resection between the initial stage III patients who became
resectable and those who presented with resectable disease.11 The
morbidity and mortality after chemoradiation therapy for initially
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locally unresectable pancreatic adenocarcinoma has not been
thoroughly investigated, and could counterbalance the potential
benefit of an R0 resection.
The objective of the present study was to compare post-
operative morbidity in a case-matched analysis between patients
with initially unresectable or borderline resectable pancreatic
cancer who were resected after pre-operative chemoradiation
therapy, and patients with resectable pancreatic cancer who
underwent a resection without previous treatment.
Material and methods
Subjects and data collection
This study was approved by the institutional review board. Demo-
graphic, radiographical and pathological data were obtained from
prospective databases with an additional retrospective medical
record review performed when necessary. All patients underwent
pre-operative radiation and a resection at the Memorial Sloan-
Kettering Cancer Center. Included in the pre-operative chemora-
diation group were patients who initially presented with either
locally unresectable or borderline resectable tumours who expe-
rienced a sufficient response with multimodality therapy to allow
a complete resection. A chart review was performed to define the
reason for initial unresectability and the method by which that
decision was made. Lesions were considered unresectable when
the vascular invasion precluded the R0 resection.12 Tumours were
defined as locally advanced based on intra-operative assessment
or on cross-sectional imaging determining extensive vascular
involvement precluding a resection. Pre-operatively, routine high-
quality abdominal and pelvic computed tomography (CT) scans
were performed. Border-line lesions were defined as those whose
tumours exhibit encasement of a short segment of the hepatic
artery, without evidence of tumour extension to the celiac axis,
that is amenable to resection and reconstruction; tumour abut-
ment of the superior mesenteric artery involving 180° of the
circumference of the artery; or short-segment occlusion of the
superior mesenteric vein, portal vein, or their confluence with a
suitable option available for vascular reconstruction because the
veins are normal above and below the area of tumour involve-
ment.12 All patients were reviewed at a weekly hepatobiliary
disease management conference attended by surgeons, oncolo-
gists, radiologists and gastroenterologists prior to resection.
Demographic characteristic as well as variables that might
influence morbidity and mortality were recorded. Weight loss was
defined to compare the weight at the time of diagnosis with the
patients’ pre-illness weight. Operative and peri-operative vari-
ables recorded included: type of resection, operative approach, the
need for vascular resection, type of reconstruction, tumour size,
estimated blood loss and total operative time. Post-operative com-
plications (90 days) were prospectively recorded in a departmental
database as previously reported.13 Complication data were then
reviewed by surgical attendings and house staff at monthly service
meetings and audited after patient discharge by a clinical nurse
specialist. In addition, the social security database was checked
quarterly to confirm mortality status. High-grade complications
were defined as any complication recorded as grade 3–5. Pancre-
atic complications included pancreatic anastomotic leak (i.e. clini-
cal signs and symptoms or radiological confirmation of a
pancreatic anastomotic leak with amylase-rich drainage >50 ml/
day beyond postoperative day 5, without development of a
fistula), pancreatic fistula (i.e. clinical signs and symptoms with
amylase-rich drainage >50 ml/day beyond post-operative day 10)
or an intra-abdominal abscess (i.e. clinical signs and symptoms or
radiological diagnosis of an intra-abdominal abscess or peritoni-
tis).14 Post-operative pancreatic fistulae were classified according
to the International Study Group on Pancreatic Fistula classifica-
tion (IGSPF).15
Matching-process
A case-matched study design was used in an attempt to eliminate the
confounding effects of clinically established factors.16 Comparisons
were performed between 29 patients who underwent a pancreatec-
tomy after pre-operative chemoradiation therapy and a matched
group of 29 patients who underwent a resection without any neoad-
juvant treatment during the same time period (2000–2010). Patients
were matched 1:1 by age, gender, the presence of comorbidities
(yes/no), American Society of Anesthesiology (ASA) score, tumour
location (head/body-tail), procedure (pancreaticoduodenectomy/
distal pancreatectomy) and vascular resection (yes/no). The selec-
tion process was random, and the investigator was blinded to the
other clinical, radiographical and outcome data.
Statistical analysis
Values were expressed as median (interquartile), or percentage, as
appropriate. Differences between the matched groups were evalu-
ated using Wilcoxon’s signed ranks test for continuous variables
and the McNemar’s chi-square test for paired proportions for
categorical variables. For all tests, statistical significance was
defined by P < 0.05. Data were analysed with the STATA 8 statis-
tical software (StataCorp, College Station, TX, USA), and match-
ing was done using the Match and Balance Match functions from
the Matching library in R (http://www.r-project.org).
Results
Between September 2001 and July 2011, 29 patients underwent a
pancreatic resection after pre-operative chemoradiation therapy
for initially locally unresectable/borderline resectable pancreatic
cancer. These were matched with 29 patients with resectable
tumours. Patients and lesion characteristics are summarized in
Table 1. Between the two groups, there were 30 females (52%) and
28 males (48%) (P = 1). Characteristics of the groups were similar
with respect to the median age at operation [66 years, p25 (60) –
p75 (72), P = 0.774], tumour location (head – 90% versus body
and tail – 10%), procedure (93% pancreaticoduodenectomy
versus 7% distal pancreatectomy) and the need for vascular resec-
tion (14%, P = 1). An ASA physical status score higher than 2
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(46%), median body mass index (BMI) (25 kg/m2), median car-
bohydrate antigen 19-9 (170 mg/dl), use of staging laparoscopy
(57%), median total operative time (291 min), median estimated
blood loss (600 ml) and administered blood transfusions (29%)
were also statistically similar.
Characteristic of patients operated after
pre-operative chemoradiation therapy for initially
locally unresectable pancreatic cancer
The characteristics of the pre-operative chemoradiation group are
shown in Table 2. Vascular encasement (>180°) was present in 17
patients and the superior mesenteric vein was the most prevalent
vessel involved in this subgroup (56%). Twenty-three patients
(80%) underwent induction chemotherapy based on gemcitabine.
All patients in this group underwent radiation therapy with con-
comitant chemotherapy [5-fluorouracil (5-FU) 28%, gemcitabine
65% and non-specified 7%]. The patients were treated with con-
formal radiation therapy (59%) or intensity-modulated radiation
therapy (IMRT, 41%). The mean total dose was 52  3 Gy. The
median duration of treatment was 38 days (ranging 35–58). The
median treatment effect within the pathological specimens was
80% [p25 (50) – p75 (95)].
Table 1 Clinicopathological and operative parameters
Characteristics Total
N = 58 (%)
Chemoradiation
N = 29 (%)
Surgery
N = 29 (%)
P-value
Age (years)a 66 (60–72) 64 (61–72) 67 (60–70) 0.77
Gender (Male) 28 (48) 14 (48) 14 (48.) 1
Body mass indexa 25 (23–28) 25 (22–28) 26 (23–28) 0.58
ASA (higher than 2) 27 (47) 14 (48) 13 (45) 1
Weight loss (%) 5 (0–10) 0 (0–8) 6 (0–10) 0.003
CA 19-9 at diagnosis (ng/dl)a 170 (49–679) 249 (80–1217) 87 (25–464) 0.33
Tumour site 1
Head 52 (90) 26 (90) 26 (90)
Tail 6 (10) 6 (10) 6 (10)
Previous cardiovascular disease 12 (21) 6 (21) 6 (21) 1
Diabetes 6 (10) 3 (10) 3 (10) 1
Pulmonary disease 2 (3.5) 1 (3.5) 1 (3.5) 1
Alb (mg/dl)a 4.1 (3.9–4.2) 4.1 (3.8–4.2) 4.1 (4–4.2) 0.49
Haemoglobin (mg/dl)a 12.4 (11.3–13.6) 11.7 (10.8–13) 13.4 (11.8–14.3) 0.03
Previous surgery 15 (26) 14 (48) 1 (3.5) <0.001
Procedure 1
Distal pancreatectomy 4 (7) 2 (7) 2 (7)
Pancreaticoduodenectomy 54 (93) 27 (93) 27 (93)
Vascular resection 8 (14) 4 (14) 4 (14) 1
Operative time (min)a 291 (255–335) 271 (251–360) 297 (260–330) 0.88
Estimated blood loss (ml)a 600 (350–1000) 600 (300–1000) 600 (355–1000) 0.24
Transfusion 17 (29) 9 (31) 8 (28) 1
Any positive margin 8 (14) 1 (3.5) 7 (24) 0.07
Tumour size (cm)a 3 (2.1–3.9) 2.5 (1.5–3) 3.2 (2.8–4.2) 0.011
T Stage 0.016
(0, 1, 2) 7 (12) 7 (24) 0
3 51 (88) 22 (76) 29 (100)
N Stage <0.001
N0 31 (53) 27 (93) 4 (14)
N1 27 (47) 2 (7) 25 (86)
Any complications 28 (48) 12 (41) 16 (55) 0.42
Any grade 3–5 complications 12 (21) 6 (21) 6 (21) 1
Presence of leaks and fistulae 5 (9) 2 (7) 3 (10) 1
90-day mortality 1 (1.7) 0 1 (3.5) 1
aMedian (interquartile). Univariate analyses: McNemar's chi-square and Wilcoxon's sign-rank tests comparing homogenicity between the case and
control groups.
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Neoadjuvant treatment plan
Chemotherapy
Among the 29 patients treated with radiation therapy, 23 patients
(80%) underwent gemcitabine-based induction chemotherapy
prior to radiation therapy. Seven patients (30%) received mono-
therapy with gemcitabine. The remaining 16 patients received
gemcitabine-based two-drug therapy (gemcitabine combined
with oxaliplatin, n = 5; cisplatin, n = 4; capecitabine, n = 3; erlo-
tinib, n = 2) or three-drug therapy (gemcitabine combined with
docetaxel and capecitabine, n = 2). The patients received a median
duration of 2 months of induction chemotherapy prior to chemo-
radiation (range, 0.2–4.2). The response to induction chemo-
therapy was evaluable on a computed tomography scan before the
start of chemoradiation in 15 patients. Seven patients had a partial
response and 8 patients had stable disease according to Response
Evaluation Criteria in Solid Tumors 1.1 criteria.17
All 29 patients received chemotherapy concurrently with radio-
therapy. Nineteen patients (65%) received concurrent gemcitab-
ine twice weekly (40 mg/m2 twice per week), with the other eight
(28%) receiving infusional 5-FU (200–225 mg/m2 daily through-
out radiation treatments) or capecitabine (1300 mg/m2 divided
into twice-daily doses given from Monday to Friday with radiation
treatment) and two patients (7%) received both drugs.
Radiotherapy
All 29 patients received radiotherapy before surgery. The radiated
volume included a radiographically apparent gross tumour and
suspicious/enlarged lymph nodes on CT simulation. The clinical
target volume included the draining lymph node basins including
celiac, superior mesenteric and retroperitoneal nodes. A planning
target volume (PTV) was generated to account for a daily setup
error and an internal tumuor motion related to respiration. A
median dose of 50.4 Gy in 28 daily fractions was delivered to the
PTV (range, 45–60 Gy). Twelve patients were treated with IMRT.
The median time from diagnosis to surgical treatment was 8
months and the median time from the end of radiation treatment
to surgery was 2.7 months.
Table 2 Pretreatment clinicoradiological characteristics (29 patients)
Characteristics Number of events (%)
Vessel encasement Vessel encasement
>180° in 17
patients (58.6%)
Superior mesenteric vein 17 (36) 10 (56)
Superior mesenteric artery 13 (28) 7 (39)
Portal vein 6 (13) —
Others 11 (22) 1 (6)
Total number of events 47 18
Neoadjuvant chemotherapy
Induction (gemcitabine) 23 (80)
Concomitant
5-FU 8 (28)
Gemcitabine 19 (65)
5 FU + Gemcitabine 2 (7)
Neoadjuvant radiation therapy
Modality
Three-dimensional 17 (59)
IMRT a 12 (42)
Total dose (Gy)
45–50.4 16 (55)
54–60 11 (38)
Non- specified 2 (7)
Total duration (days)b 38 (37–41)
Time from diagnosis to resection (months)a 8 (6–9.3)
Time from the end of radiation to resection (months)a 2.7 (1.9–4.1)
Pathological treatment effect (%)a 80 (50–95)
aMedian (interquartile).
IMRT, intensity-modulated radiation therapy.
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Adverse events and toxicity
During chemoradiotherapy, treatment-related grade 3 or 4
adverse events according to the National Cancer Institute
Common Terminology Criteria for Adverse Events (version 4.0)
occurred in two patients (7%) with one case of grade 3 nausea and
one case of grade 3 gastritis.
Matched-cohort analysis of post-operative
morbidity after a pancreatectomy with or
without neoadjuvant treatment
Both groups were comparable regarding age, gender, comorbidi-
ties (renal failure, neurological disorders, bleeding disorder,
hypothyroidism, liver disease, depended functional healthy status
and previous sepsis, cardiac congestive failure, diabetes mellitus,
pulmonary disease), tumour location and procedure, the need for
vascular resection, ASA group and BMI, as shown in Table 1. The
variables of previous surgery, pathological parameters such as
tumour size, the presence of positive margins and nodal stage,
were different between the groups; however, these factors have not
been clearly shown to be associated with post-operative compli-
cations. Post-operative complications are also presented in
Table 1. Post-operative complications occurred in 48% of patients
[41 (chemoradiation group) versus 55 (surgery group), P = 0.42].
The presence of complications grade 3–5 was 21% in both groups,
(P = 1). Specifically, the presence of a pancreatic leak and fistula
was 9% [7 (chemoradiation group) versus 10 (surgery group), P =
1], and mortality at 90-day was 1.7% [0 (chemoradiation group)
versus 3.5 (surgery group), P = 1].
The distribution of complications by organ system is presented
in Table 3. In general, the most prevalent complications by body
system recorded were in the wound or skin category with 34%
experiencing a wound complication. In the control group, the
most prevalent category was also wound or skin with 48% and in
the chemoradiation group were the gastrointestinal system cat-
egory with 36%. When only grade 3–5 complications were evalu-
ated, the gastrointestinal system was the most common with 35%
of complications grade 3–5 (33% in the chemoradiation group
versus 29% in the surgery group). Table 3b summarizes the com-
plications related to pancreatic leaks and fistulae classified by the
International Study Group on Pancreatic Fistula criteria. Five
leaks were recorded; two grade B [1 (chemoradiation group)
versus 1 (surgery group)] and three grade C [1 (chemoradiation
group) versus 2 (surgery group)]. The median length of stay was 7
days (range 5–26). Post-operative mortality occurred in a single
patient who died secondary to cardiovascular events in the control
group.
Discussion
Although by definition neoadjuvant therapy is intended to be
delivered to patients with resectable disease, patients with unre-
sectable disease have been included in several series of ‘neoadju-
vant therapy’ in pancreatic cancer.10,18,19 The primary goal in
delivering radiation to patients with locally unresectable tumours
is to change patients from an unresectable to resectable state, with
the hope that their prognosis will improve. Guillen et al. in a
recent meta-analysis of neoadjuvant therapy in patients with
locally unresectable pancreatic cancer, found that patients with
locally advanced disease who underwent a resection after neoad-
juvant treatment have the same median survival as patients
with initially resectable disease; 20.5 and 20.1–23.6 months,
respectively.18
In this study, intra-operative and clinicopathological data
analyses suggest that complications are statistically similar
Table 3a Morbidity and 90-day mortality in the 58 patients with complications recorded by body systems
System Total complications (%) Complication crades 3–5 (%)
Chemoradiation Surgery Chemoradiation Surgery
Gastrointestinal 8 (36) 3 (14) 3 (33) 2 (29)
Wound or skin 4 (18) 10 (48) — 1 (14)
Infection 3 (14) 4 (19) 2 (22) 2 (29)
Cardiovascular 3 (14) 1 (5) 2 (22) 1 (14)
Haematological/vascular 2 (9.) 1 (5) 2 (22) —
Others 2 (9) 2 (10) — 1 (14)
Number of events 22 21 9 7
Table 3b Leak and fistula rates
ISGPF classification Total complications (%) Chemoradiation Surgery
A 0 0 0
B 2 (40) 1 (50) 1 (33)
C 3 (60) 1 (50) 2 (67)
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between patients who were initially resectable and those who
receive chemoradiation for locally unresectable or borderline
disease. These data suggest that neoadjuvant chemoradiation
therapy, in selected patients, should be considered as a therapeutic
tool that does not increase post-operative complications rates.
Gemcitabine has been utilized as a radiation sensitizer. Animal
studies from the University of Michigan and MD Anderson
Cancer Center have suggested that maximum radiation sensitiza-
tion with gemcitabine is achieved with a lower dose administered
twice weekly. This has been evaluated in several phase I and II
trials and has been utilized by this group.4,20–26 The strength of
these data lie within the matching process which was based on
pre-operative variables previously found to be associated with
post-operative morbidity and mortality.27–29 Variables such as
weight loss, haemoglobin, previous surgery, the largest diameter
of the tumour, and pathological T and N stages are critical in the
matching process as they may reflect the more advanced nature of
locally unresectable or borderline disease. Reported rates of
venous resection and reconstruction vary in the literature from
12% to 65%, based on a recent meta-analysis published this year.30
The present data were not particularly surprising as most of these
resected patients have been heavily pre-treated with both chemo-
therapy and chemoradiation. Other pathological findings that
suggest a local effect of therapy is as a result of the fact that the vast
majority of the patients were node negative. Furthermore, they
did not change the extent of resection as procedures and the need
for a vascular resection fitted well in the matching process. Dif-
ferences in pathological data (T and N stage) were significantly
different between the groups, and were considered as effects of
pre-operative treatment.
The limitations of the study are those of a retrospective study,
with a small sample size consequent to the matching process and
this fact is a significant limitation of this study. The present data-
base only identifies patients who are taken to the operating room
for either exploration or resection. Therefore only patients who
presented with downstaging and were able to undergo a resection
(29/865 patients) could be accurately identified. It can be reasoned
that downstaging is a rare event in our experience (5%), but the
progression of disease rate could not be estimated.
It is agreed that the patients in this study represent a highly
selected group. The fact that more patients in the pre-treatment
group had undergone prior abdominal surgery is inherent to the
condition of unresectable or border-line lesions at presentation.
Regarding the difference of tumour size, the measures were col-
lected based on the pathological findings only, after a treatment
effect had been detected. Unfortunately, the initial measures on
imaging were not fully described and we assume this as a limita-
tion of this retrospective study. Complications may also have been
underestimated if they occurred after discharge and the patient
was followed up elsewhere. However, in this case this would be
expected to be distributed equally between both groups.
In summary, although some previous studies have suggested
differences in post-operative morbidity between these groups of
patients, our case-match analysis did not find statistical differ-
ences in surgical morbidity and mortality associated with neoad-
juvant chemoradiation therapy for patients with locally advanced
pancreas cancer. Therefore it is felt that a resection should be
considered for patients with locally unresectable/borderline pan-
creas cancer who are felt to be resectable after chemoradiation.
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